S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Anavex Life Sciences Stock Forecast, Price & News

-0.27 (-2.13%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.20 million shs
Average Volume
1.04 million shs
Market Capitalization
$941.10 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Anavex Life Sciences logo

About Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.


Anavex Life Sciences (NASDAQ:AVXL) Shares Up 5.9%
January 19, 2022 |  americanbankingnews.com
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap Down to $14.39
January 18, 2022 |  americanbankingnews.com
Earnings Outlook For Anavex Life Sciences
November 23, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$1.99 per share


Net Income
$-37.91 million
Pretax Margin




Free Float
Market Cap
$941.10 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.99 out of 5 stars

Medical Sector

646th out of 1,419 stocks

Commercial Physical Research Industry

14th out of 27 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

Is Anavex Life Sciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Anavex Life Sciences stock.
View analyst ratings for Anavex Life Sciences
or view top-rated stocks.

How has Anavex Life Sciences' stock been impacted by COVID-19?

Anavex Life Sciences' stock was trading at $3.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AVXL stock has increased by 272.9% and is now trading at $12.38.
View which stocks have been most impacted by COVID-19

When is Anavex Life Sciences' next earnings date?

Anavex Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Anavex Life Sciences

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) released its earnings results on Wednesday, November, 24th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.15). During the same period last year, the firm posted ($0.10) earnings per share.
View Anavex Life Sciences' earnings history

What price target have analysts set for AVXL?

6 analysts have issued 12 month price objectives for Anavex Life Sciences' shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate Anavex Life Sciences' share price to reach $33.83 in the next twelve months. This suggests a possible upside of 173.3% from the stock's current price.
View analysts' price targets for Anavex Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Anavex Life Sciences' key executives?

Anavex Life Sciences' management team includes the following people:
  • Christopher U. Missling, Chairman, President, CEO & Secretary
  • Stephan Toutain, Chief Operating Officer
  • Sandra Boenisch, Principal Financial Officer & Treasurer
  • Walter E. Kaufmann, Chief Scientific Officer
  • Edward R. Hammond, Chief Medical Officer

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), CytRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Investors Financial Group LLC (0.05%) and Liberty One Investment Management LLC (0.01%). Company insiders that own Anavex Life Sciences stock include Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends for Anavex Life Sciences

Which institutional investors are buying Anavex Life Sciences stock?

AVXL stock was bought by a variety of institutional investors in the last quarter, including Investors Financial Group LLC, and Liberty One Investment Management LLC.
View insider buying and selling activity for Anavex Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $12.38.

How much money does Anavex Life Sciences make?

Anavex Life Sciences has a market capitalization of $941.10 million. The biotechnology company earns $-37.91 million in net income (profit) each year or ($0.53) on an earnings per share basis.

How many employees does Anavex Life Sciences have?

Anavex Life Sciences employs 20 workers across the globe.

What is Anavex Life Sciences' official website?

The official website for Anavex Life Sciences is www.anavex.com.

Where are Anavex Life Sciences' headquarters?

Anavex Life Sciences is headquartered at 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at (844) 689-3939 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.